

CLAIMS

What is claimed is:

1. An isolated and purified biologically active *piwi* family polypeptide comprising:
 - 5 (a) a polypeptide encoded by a nucleic acid sequence as set forth in any of SEQ ID NOs:1, 3 and 5;
 - (b) a polypeptide encoded by a nucleic acid having at least about 75% or greater homology to a DNA sequence as set forth in any of SEQ ID NOs:1, 3 and 5;
 - 10 (c) a polypeptide encoded by a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a sequence or the complement of a sequence as set forth in any of SEQ ID NOs:1, 3 and 5;
 - (d) a polypeptide which is a biologically functional equivalent of a peptide as set forth in any of SEQ ID NOs:2, 4 and 6;
 - 15 (e) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with peptides encoded by the nucleic acid sequences as set forth in any of SEQ ID NOs:2, 4 and 6;
 - 20 (f) a polypeptide encoded by a nucleic acid molecule capable of hybridizing to a nucleic acid molecule having the sequence of any of SEQ ID NOs:1, 3 and 5, or fragments or variants or complementary sequences thereof, under high stringency conditions; or
 - 25 (g) a polypeptide comprising a portion of a polypeptide of a), b), c), d), e), or f).
2. The polypeptide of claim 1, wherein the polypeptide comprises a vertebrate *piwi* family polypeptide.
3. The polypeptide of claim 2, wherein the polypeptide comprises a
30 human *piwi* family polypeptide.

093737 060401
T04090" 4E4E4860

4. The polypeptide of claim 1, wherein the *piwi* family comprises an amino acid sequence as set forth in any of SEQ ID NOs:2, 4 and 6.
5. The polypeptide of claim 1, modified to be in detectably labeled form.
- 5 6. An isolated and purified antibody capable of specifically binding to the polypeptide of claim 1.
7. The antibody of claim 6 which is a monoclonal antibody.
8. The antibody of claim 6 which is a polyclonal antibody.
9. A hybridoma cell line which produces the monoclonal antibody of
- 10 claim 8.
10. An isolated and purified antibody capable of neutralizing the biological activity of the polypeptide of claim 1.
11. The antibody of claim 10 which is a monoclonal antibody.
12. The antibody of claim 10 which is a polyclonal antibody.
- 15 13. A hybridoma cell line which produces the monoclonal antibody of claim 11.
14. An isolated and purified polynucleic acid encoding a biologically active *piwi* family polypeptide of claim 1.
15. The polynucleic acid of claim 14, wherein the encoded
- 20 polypeptide comprises a vertebrate *piwi* family polypeptide.
16. The polynucleic acid of claim 15, wherein the encoded polypeptide comprises a mammalian *piwi* family polypeptide.
17. The polynucleic acid of claim 16, wherein the encoded polypeptide comprises a human *piwi* family polypeptide.
- 25 18. The polynucleic acid of claim 14, wherein the encoded polypeptide comprises an amino acid sequence as set forth in any of SEQ ID NOs:2, 4 and 6.

097373 060401

19. The polynucleic acid of claim 18, further comprising a *piwi* family-encoding polynucleic acid sequence as set forth in any of SEQ ID NOs:1, 3 and 5.

5 20. The polynucleic acid of claim 14, further defined as a DNA segment.

21. The polynucleic acid of claim 14, further defined as positioned under the control of a promoter.

22. The polynucleic acid of claim 14, further defined as a recombinant vector.

10 23. The polynucleic acid of claim 22, wherein the vector is a recombinant expression vector.

24. The polynucleic acid of claim 22, further defined as a nucleic acid fragment of up to 50,000 basepairs in length.

15 25. The polynucleic acid of claim 24, further defined as comprising at least a 1,000 nucleotide long contiguous stretch of a polynucleic acid sequence as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

26. A recombinant host cell comprising the polynucleic acid of claim 14.

20 27. The recombinant host cell of claim 26, wherein the host cell is a procaryotic cell.

28. The recombinant host cell of claim 26, wherein the host cell is a eukaryotic cell.

25 29. A method of preparing a *piwi* family polypeptide, comprising: transforming a cell with the polynucleic acid of claim 14 to produce a *piwi* family under conditions suitable for the expression of said polypeptide.

30. A method of detecting in a sample an RNA that encodes the *piwi* family polypeptide encoded by the nucleic acid of claim 14, said method comprising the steps of:

- (a) contacting said sample under hybridizing conditions with the polynucleic acid of claim 14 to form a duplex; and
- (b) detecting the presence of said duplex.

31. A method of producing an antibody immunoreactive with a *piwi*
5 family polypeptide, the method comprising steps of:

- (a) transfecting a recombinant host cell with the a polynucleic acid of claim 14, which encodes a *piwi* family polypeptide;
- (b) culturing the host cell under conditions sufficient for expression of the polypeptide;
- 10 (c) recovering the polypeptide; and
- (d) preparing the antibody to the polypeptide.

32. The method of claim 31, wherein the polypeptide comprises a polypeptide as essentially set forth in any of SEQ ID NOs:2, 4 and 6.

33. The method of claim 31, wherein the polynucleic acid comprises
15 a polynucleic acid sequence as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

34. An antibody produced by the method of claim 31.

35. A method of detecting a *piwi* family polypeptide, the method comprising immunoreacting the polypeptide with an antibody prepared
20 according the method of claim 31 to form an antibody-polypeptide conjugate; and detecting the conjugate.

36. A method of detecting a messenger RNA transcript that encodes a *piwi* family polypeptide, the method comprising the steps of hybridizing the messenger RNA transcript with the polynucleic acid of claim 14 to form a
25 duplex; and detecting the duplex.

37. A method of detecting a DNA molecule that encodes a *piwi* family polypeptide, the method comprising the steps of hybridizing DNA molecules with the polynucleic acid of claim 14 to form a duplex; and detecting the duplex.

09373-06040-1
F04090" 2E2E2860

38. An assay kit for detecting the presence of a *piwi* family polypeptide in a biological sample, the kit comprising a first container containing a first antibody capable of immunoreacting with a *piwi* family polypeptide of claim 1, wherein the first antibody is present in an amount
5 sufficient to perform at least one assay.

39. The assay kit of claim 38, further comprising a second container containing a second antibody that immunoreacts with the first antibody.

40. The assay kit of claim 39, wherein the first antibody and the second antibody comprise monoclonal antibodies.

10 41. The assay kit of claim 39, wherein the first antibody is affixed to a solid support.

42. The assay kit of claim 39, wherein the first and second antibodies each comprise an indicator.

15 43. The assay kit of claim 42, wherein the indicator is a radioactive label, a fluorescent label or an enzyme.

44. An assay kit for detecting the presence, in biological samples, of a *piwi* family polypeptide, the kit comprising a first container that contains a polynucleic acid identical or complimentary to a segment of at least ten contiguous nucleotide bases of the polynucleic acid of claim 14.

20 45. An assay kit for detecting the presence, in a biological sample, of an antibody immunoreactive with a *piwi* family polypeptide, the kit comprising a first container containing a *piwi* family polypeptide of claim 1 that immunoreacts with the antibody, with the polypeptide present in an amount sufficient to perform at least one assay.

25 46. A method of screening candidate substances for an ability to modulate *piwi* family biological activity, the method comprising the steps of:

- (a) establishing replicate test and control samples that comprise a biologically active *piwi* family polypeptide;
- (b) administering a candidate substance to the test sample
30 but not the control sample;

- 5

10

48.

49.

15

20

25

53

54

55. The method of claim 50, wherein the *piwi* family activity comprises modulating cell growth, proliferation, division and combinations thereof, and wherein the step of administering comprises administering to the subject an effective *piwi* family-modulating amount of a *piwi* family-modulating substance.

56. The method of claim 50, wherein the subject is a vertebrate.

57. The method of claim 56, wherein the vertebrate is a warm-blooded vertebrate.

58. A method of treating a subject suffering from a disorder associated with *piwi* family biological activity, the method comprising: administering to the subject an effective amount of a *piwi* family biological activity-modulating substance, whereby treatment of the disorder is accomplished.

59. The method of claim 58, wherein the step of administering further comprises administering an effective amount of a substance that modulates expression of a *piwi* family-encoding polynucleic acid in the subject.

60. The method of claim 59, wherein the substance that modulates expression of a *piwi* family-encoding polynucleic acid comprises an antisense oligonulceotide.

61. The method of claim 58, wherein the substance capable of modulating *piwi* family activity in the subject comprises an anti-*piwi* family antibody.

62. The method of claim 61, wherein the anti-*piwi* family antibody comprises a monoclonal antibody.

63. A method of treating a subject suffering from a disorder associated with *piwi*-mediated biological activity, the method comprising administering to the subject a therapeutic composition which comprises a biologically active *piwi* family polypeptide, whereby treatment of disorder associated with *piwi*-mediated biological activity in the subject is accomplished.

64. The method of claim 63, wherein the therapeutic composition comprises a biologically active *piwi* family polypeptide and a pharmaceutically acceptable carrier.

5 65. The method of claim 63, wherein the *piwi*-mediated biological activity comprises modulation of stem cell growth, proliferation, division and combinations thereof, modulation of primordial germ cell proliferation, and combinations thereof; and the *piwi* family polypeptide is administered in an effective amount.

10 ~~64~~ 65. A method for modulating *piwi*-mediated biological activity in a cell, the method comprising:

(a) delivering to the cell an effective amount of a DNA molecule comprising a polynucleotide that encodes a biologically active *piwi* family polypeptide; and

15 (b) maintaining the cell under conditions sufficient for expression of said polypeptide.

~~65~~ 66. The method of claim ~~65~~⁶⁶, wherein the polypeptide comprises a polypeptide as essentially set forth in any of SEQ ID NOs:2, 4 and 6.

~~66~~ 67. The method of claim ~~66~~⁶⁷, wherein the polypeptide is encoded by a polynucleic acid as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

20 ~~67~~ 68. A method of culturing a primitive cell, the method comprising:

(a) providing a culture comprising a primitive cell; and

(b) delivering to the primitive cell a *piwi* family gene product, whereby growth of the primitive cell in a culture is accomplished.

25 ~~68~~ 69. The method of claim ~~68~~⁶⁹, wherein the primitive cell is maintained in the culture for a time sufficient to produce a sustained cell culture.

~~69~~ 70. The method of claim ~~69~~⁷⁰, wherein the *piwi* family gene product is delivered to the primitive cell by delivering to the primitive cell an effective amount of a polynucleotide that encodes a biologically active *piwi* family

1040990 2E2E2B50

71.

69
68

93
72.

69
68

(b) depositing the primitive cells in contact with a feeder matrix, the feeder matrix comprising a *piwi* family gene product; and

(c)

74
73.

69

family
75
74.

76
75.

75.

77.

76
75.

18

70728.

76
75

number of germline stem cells or primordial germ cells in the animal as compared to a normal animal.

5 ~~78~~⁷⁹. The transgenic or chimeric non-human animal of claim ~~75~~⁷⁶, further comprising an additional polynucleic acid encoding a predetermined biologically active polypeptide, the polynucleic acid being present in said genome in a copy number effective to confer expression in the animal of the polypeptide.

~~80~~⁸¹. A method of altering the phenotype of an embryonic animal, the method comprising:

- 10 (a) providing a recombinant primitive cell comprising a polynucleic acid encoding a biologically active *piwi* family polypeptide;
- (b) transfecting the recombinant primitive cell with a polynucleic acid encoding a predetermined biologically active polypeptide;
- 15 (c) transferring the transfected primitive cells into an embryo to confer expression of the predetermined biologically active polypeptide animal of the polypeptide, whereby the phenotype of the embryo is altered.

~~82~~⁸³. The method of claim ~~80~~⁷⁹, wherein the animal is a bird, and the transfected primitive cell is transferred into an egg containing an embryonic bird.

20 ~~82~~⁸³. The method of claim ~~80~~⁷⁹, wherein the altered phenotype comprises a change in protein expression, a change in growth rate, feed efficiency, a change in stem cell count, a change in primordial germ cell count, disease resistance, or a combination thereof.

~~83~~⁸⁴. The method of claim ~~80~~⁷⁹, wherein the embryonic animal is permitted to develop into a fetus or animal.

25 ~~84~~⁸⁵. A method of recovering a protein from a transgenic or chimeric non-human animal, the method comprising:

- 30 (a) providing a transgenic or chimeric non-human animal having incorporated into its genome a polynucleic acid encoding a biologically active *piwi* family polypeptide, the polynucleic acid

093737 060401
104090" 2E2E2E60

(b) recovering the biologically active *piwi* family polypeptide from the animal provided in step (a).

85. The method of claim 84, wherein the transgenic or chimeric non-human animal provided in step (a) further comprises another polynucleic acid incorporated into its genome, the polynucleic acid encoding a predetermined biologically active polypeptide, the polynucleic acid being present in said genome in a copy number effective to confer expression in the animal of the predetermined polypeptide; and wherein the predetermined biologically active polypeptide is recovered in addition to or instead of the biologically active *piwi* family polypeptide.

family polypeptide.

85 86
87 88
89 90
91 92
93 94
95 96
97 98
99 100
101 102
103 104
105 106
107 108
109 110
111 112
113 114
115 116
117 118
119 120
121 122
123 124
125 126
127 128
129 130
131 132
133 134
135 136
137 138
139 140
141 142
143 144
145 146
147 148
149 150
151 152
153 154
155 156
157 158
159 160
161 162
163 164
165 166
167 168
169 170
171 172
173 174
175 176
177 178
179 180
181 182
183 184
185 186
187 188
189 190
191 192
193 194
195 196
197 198
199 200
201 202
203 204
205 206
207 208
209 210
211 212
213 214
215 216
217 218
219 220
221 222
223 224
225 226
227 228
229 230
231 232
233 234
235 236
237 238
239 240
241 242
243 244
245 246
247 248
249 250
251 252
253 254
255 256
257 258
259 260
261 262
263 264
265 266
267 268
269 270
271 272
273 274
275 276
277 278
279 280
281 282
283 284
285 286
287 288
289 290
291 292
293 294
295 296
297 298
299 300
301 302
303 304
305 306
307 308
309 310
311 312
313 314
315 316
317 318
319 320
321 322
323 324
325 326
327 328
329 330
331 332
333 334
335 336
337 338
339 340
341 342
343 344
345 346
347 348
349 350
351 352
353 354
355 356
357 358
359 360
361 362
363 364
365 366
367 368
369 370
371 372
373 374
375 376
377 378
379 380
381 382
383 384
385 386
387 388
389 390
391 392
393 394
395 396
397 398
399 400
401 402
403 404
405 406
407 408
409 410
411 412
413 414
415 416
417 418
419 420
421 422
423 424
425 426
427 428
429 430
431 432
433 434
435 436
437 438
439 440
441 442
443 444
445 446
447 448
449 450
451 452
453 454
455 456
457 458
459 460
461 462
463 464
465 466
467 468
469 470
471 472
473 474
475 476
477 478
479 480
481 482
483 484
485 486
487 488
489 490
491 492
493 494
495 496
497 498
499 500
501 502
503 504
505 506
507 508
509 510
511 512
513 514
515 516
517 518
519 520
521 522
523 524
525 526
527 528
529 530
531 532
533 534
535 536
537 538
539 540
541 542
543 544
545 546
547 548
549 550
551 552
553 554
555 556
557 558
559 560
561 562
563 564
565 566
567 568
569 570
571 572
573 574
575 576
577 578
579 580
581 582
583 584
585 586
587 588
589 590
591 592
593 594
595 596
597 598
599 600
601 602
603 604
605 606
607 608
609 610
611 612
613 614
615 616
617 618
619 620
621 622
623 624
625 626
627 628
629 630
631 632
633 634
635 636
637 638
639 640
641 642
643 644
645 646
647 648
649 650
651 652
653 654
655 656
657 658
659 660
661 662
663 664
665 666
667 668
669 670
671 672
673 674
675 676
677 678
679 680
681 682
683 684
685 686
687 688
689 690
691 692
693 694
695 696
697 698
699 700
701 702
703 704
705 706
707 708
709 710
711 712
713 714
715 716
717 718
719 720
721 722
723 724
725 726
727 728
729 730
731 732
733 734
735 736
737 738
739 740
741 742
743 744
745 746
747 748
749 750
751 752
753 754
755 756
757 758
759 760
761 762
763 764
765 766
767 768
769 770
771 772
773 774
775 776
777 778
779 780
781 782
783 784
785 786
787 788
789 790
791 792
793 794
795 796
797 798
799 800
801 802
803 804
805 806
807 808
809 810
811 812
813 814
815 816
817 818
819 820
821 822
823 824
825 826
827 828
829 830
831 832
833 834
835 836
837 838
839 840
841 842
843 844
845 846
847 848
849 850
851 852
853 854
855 856
857 858
859 860
861 862
863 864
865 866
867 868
869 870
871 872
873 874
875 876
877 878
879 880
881 882
883 884
885 886
887 888
889 890
891 892
893 894
895 896
897 898
899 900
901 902
903 904
905 906
907 908
909 910
911 912
913 914
915 916
917 918
919 920
921 922
923 924
925 926
927 928
929 930
931 932
933 934
935 936
937 938
939 940
941 942
943 944
945 946
947 948
949 950
951 952
953 954
955 956
957 958
959 960
961 962
963 964
965 966
967 968
969 970
971 972
973 974
975 976
977 978
979 980
981 982
983 984
985 986
987 988
989 990
991 992
993 994
995 9

86. A pharmaceutical composition comprising an isolated and purified biologically active *piwi* family polypeptide and a pharmaceutically acceptable carrier.

20 ⁸⁷ 87. The pharmaceutical composition of claim ⁸⁷ 86, wherein the polypeptide comprises a polypeptide as essentially set forth in any of SEQ ID NOs:2, 4 and 6.

88. The pharmaceutical composition of claim 86, wherein the polypeptide is encoded by a polynucleic acid sequence as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

25 in any of SEQ ID NOS. 1, 5 and 6.
 26 89. The pharmaceutical composition of claim 86, further comprising a
 27 cell expressing the polypeptide.

92
90. A pharmaceutical composition comprising an isolated and purified polynucleic acid encoding a biologically active *piwi* family polypeptide and a pharmaceutically acceptable carrier.

⁹³
~~91~~. The pharmaceutical composition of claim ⁹²~~90~~, wherein the encoded polypeptide comprises an amino acid sequence as essentially set forth in any of SEQ ID NOs:2, 4 and 6.

⁹⁴
~~92~~. The pharmaceutical composition of claim ⁹²~~90~~, further comprising a
5 *piwi* family-encoding polynucleic acid sequence as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

⁹⁵
~~93~~. The pharmaceutical composition of claim ⁹²~~90~~, wherein the polynucleic acid is a DNA segment.

⁹⁶
~~94~~. The pharmaceutical composition of claim ⁹²~~90~~, wherein the
10 polynucleic acid is positioned under the control of a promoter.

⁹⁷
~~95~~. The pharmaceutical composition of claim ⁹²~~90~~, wherein the polynucleic acid further comprises a recombinant vector.

⁹⁸
~~96~~. The pharmaceutical composition of claim ⁹²~~90~~, further comprising a
cell expressing the encoded polypeptide.

09873737 060401